AU3855297A - Pharmaceutical composition for treating papillomavirus tumours and infection - Google Patents

Pharmaceutical composition for treating papillomavirus tumours and infection

Info

Publication number
AU3855297A
AU3855297A AU38552/97A AU3855297A AU3855297A AU 3855297 A AU3855297 A AU 3855297A AU 38552/97 A AU38552/97 A AU 38552/97A AU 3855297 A AU3855297 A AU 3855297A AU 3855297 A AU3855297 A AU 3855297A
Authority
AU
Australia
Prior art keywords
infection
pharmaceutical composition
polypeptide
tumours
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU38552/97A
Other versions
AU736720B2 (en
Inventor
Jean-Marc Balloul
Nadine Bizouarne
Marie-Paule Kieny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9494633&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU3855297(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Transgene SA filed Critical Transgene SA
Publication of AU3855297A publication Critical patent/AU3855297A/en
Application granted granted Critical
Publication of AU736720B2 publication Critical patent/AU736720B2/en
Priority to AU87237/01A priority Critical patent/AU781653B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

Composition (A) for treating or preventing infections or tumours caused by papilloma virus (PV) contains as active ingredient: (a) ≥ 1 polypeptide (I) from the early region of PV and ≥ 1 polypeptide (II) from the late region of PV, or (b) ≥ 1 (I) and/or (II) plus a polypeptide (III) with immunostimulating activity. Also claimed are similar compositions containing vectors having inserts that encode (I)-(III).
AU38552/97A 1996-07-30 1997-07-29 Pharmaceutical composition for treating papillomavirus tumours and infection Ceased AU736720B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU87237/01A AU781653B2 (en) 1996-07-30 2001-11-01 Pharmaceutical composition for treating papollomavirus tumour and infection

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9609584A FR2751879B1 (en) 1996-07-30 1996-07-30 PHARMACEUTICAL COMPOSITION AGAINST TUMORS AND PAPILLOMAVIRUS INFECTIONS
FR96/09584 1996-07-30
PCT/FR1997/001412 WO1998004705A1 (en) 1996-07-30 1997-07-29 Pharmaceutical composition for treating papillomavirus tumours and infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU87237/01A Division AU781653B2 (en) 1996-07-30 2001-11-01 Pharmaceutical composition for treating papollomavirus tumour and infection

Publications (2)

Publication Number Publication Date
AU3855297A true AU3855297A (en) 1998-02-20
AU736720B2 AU736720B2 (en) 2001-08-02

Family

ID=9494633

Family Applications (1)

Application Number Title Priority Date Filing Date
AU38552/97A Ceased AU736720B2 (en) 1996-07-30 1997-07-29 Pharmaceutical composition for treating papillomavirus tumours and infection

Country Status (12)

Country Link
EP (2) EP1149910B1 (en)
JP (2) JP4070815B2 (en)
AT (2) ATE205881T1 (en)
AU (1) AU736720B2 (en)
CA (1) CA2234263C (en)
DE (2) DE69728914T2 (en)
DK (2) DK1149910T3 (en)
ES (2) ES2215805T3 (en)
FR (1) FR2751879B1 (en)
HK (1) HK1043809B (en)
PT (2) PT862634E (en)
WO (1) WO1998004705A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
CA2335506A1 (en) * 1998-06-26 2000-01-06 Aventis Pasteur Mucosal targeting immunisation
DK2530161T3 (en) * 2006-06-20 2018-06-06 Transgene Sa Process for the preparation of poxviruses and poxvirus compositions
BRPI1006901A2 (en) 2009-01-20 2016-02-16 Transgène S A ex vivo method and kit for testing if a patient will respond therapeutically to a treatment method, and use of sicam-1 levels in a blood sample
HUE026194T2 (en) 2009-03-24 2016-05-30 Transgene Sa Biomarker for monitoring patients
RU2555340C2 (en) 2009-04-17 2015-07-10 Трансжене Са Biomarker for patient monitoring
CA2761457A1 (en) 2009-05-12 2010-11-18 Transgene Sa Immortalized avian cell lines and use thereof
DK2452194T3 (en) 2009-07-10 2015-11-30 Transgene Sa Biomarker PATIENT SELECTION AND RELATED PRACTICES
SG178090A1 (en) 2009-07-21 2012-03-29 Transgene Sa Enzymatic composition for the digestion of chicken embryos
TWI690322B (en) 2012-10-02 2020-04-11 法商傳斯堅公司 Virus-containing formulation and use thereof
MX2017007178A (en) 2014-12-01 2017-08-28 Transgene Sa Stable liquid vaccinia virus formulations.
FR3042121A1 (en) * 2015-10-08 2017-04-14 Jean-Marc Limacher ANTI-TUMOR COMPOSITION
CA3062549A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
KR20200003921A (en) 2017-05-15 2020-01-10 얀센 백신스 앤드 프리벤션 비.브이. Stable Virus-Containing Compositions
CA3111273C (en) 2018-09-06 2024-03-26 Bavarian Nordic A/S Storage improved poxvirus compositions
WO2021180943A1 (en) 2020-03-12 2021-09-16 Bavarian Nordic A/S Compositions improving poxvirus stability

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2643817B1 (en) * 1989-03-06 1993-12-17 Transgene Sa PHARMACEUTICAL COMPOSITION, USEFUL AS A PREVENTIVE OR CURATIVE AGAINST TUMORS INDUCED BY PAPILLOMAVIRUS
AU650868B2 (en) † 1990-03-20 1994-07-07 Behringwerke Aktiengesellschaft Seroreactive epitopes of human papillomavirus (HPV) 16 proteins
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
DE122007000019I1 (en) * 1991-07-19 2007-07-26 Univ Queensland Vaccines against papillomavirus
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
GB9306731D0 (en) * 1993-03-31 1993-05-26 Cancer Res Campaign Tech Vaccines
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide vaccne for papillomavirus
CA2201592A1 (en) * 1994-10-03 1996-04-18 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
FR2749323B1 (en) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc PSEUDO-PARTICLES VIRALES USEFUL AS A VECTOR OF NUCLEIC ACID DELIVERY

Also Published As

Publication number Publication date
HK1043809B (en) 2004-12-03
PT862634E (en) 2002-03-28
DK1149910T3 (en) 2004-08-02
DE69728914D1 (en) 2004-06-03
JP4198735B2 (en) 2008-12-17
EP0862634B1 (en) 2001-09-19
JP4070815B2 (en) 2008-04-02
ES2163795T3 (en) 2002-02-01
DE69728914T2 (en) 2005-04-07
CA2234263C (en) 2009-10-13
FR2751879B1 (en) 1998-10-30
ES2215805T3 (en) 2004-10-16
WO1998004705A1 (en) 1998-02-05
JP2007254474A (en) 2007-10-04
AU736720B2 (en) 2001-08-02
EP0862634A1 (en) 1998-09-09
CA2234263A1 (en) 1998-02-05
EP1149910A1 (en) 2001-10-31
EP1149910B1 (en) 2004-04-28
EP0862634B2 (en) 2006-03-01
DE69706825T2 (en) 2002-05-02
DE69706825T3 (en) 2006-08-24
DK0862634T3 (en) 2002-01-21
ATE205881T1 (en) 2001-10-15
DK0862634T4 (en) 2006-05-08
HK1043809A1 (en) 2002-09-27
PT1149910E (en) 2004-09-30
JP2000500662A (en) 2000-01-25
ATE265535T1 (en) 2004-05-15
FR2751879A1 (en) 1998-02-06
DE69706825D1 (en) 2001-10-25
ES2163795T5 (en) 2006-07-16

Similar Documents

Publication Publication Date Title
AU3855297A (en) Pharmaceutical composition for treating papillomavirus tumours and infection
AU2823292A (en) Substituted biphenylpyridones
CA2183972A1 (en) Oxazolidinone derivatives and pharmaceutical compositions containing them
UA39158C2 (en) derivatives of N4-oxycarbonyl- 5'-deoxy-5-fluorocytidine and pharmaceutical preparation based thereon
AU6783698A (en) Polyaromatic antiviral compositions
AU5669198A (en) Cyclosporin derivative, its preparation and pharmaceutical compositions containing same
AU7535798A (en) Novel cyclosporin derivatives, preparation and pharmaceutical compositions containing same
AU2843689A (en) 2-(2-hydroxy-3-phenoxypropylamino) ethylphenoxymethyl compounds
AU589939B2 (en) Medical composition for injection containing a spergualin as active ingredient and process for preparing the same
AU9744298A (en) Substituted tetrahydronaphthaline and analogous compounds
AU1705392A (en) Substituted diaminophthalimides and analogues
MY120683A (en) New phenylamidine derivatives, processes for their preparation and their use as pharmaceuticals.
MY106231A (en) Antiviral tetrahydroimidazo [1,4] benzodiazepin-2- thiones.
CA2027814A1 (en) Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
CA2114859A1 (en) Cytotoxic and antiviral compound
UA74388C2 (en) Pharmaceutical compositions of tysoxanide and nitasoxanide
ZA953584B (en) Novel active peptide and its preparation
AU6722498A (en) Disubstituted biphenyloxazolines
TW249802B (en)
WO1998023574A8 (en) Asiatic acid derivatives and medicines for treating wounds, which contains the same
AU7533394A (en) Antiacid pharmaceutical composition in the form of a suspension based on sucralphate gel
AU7610194A (en) Thiocarbamoyl compounds used as antimicrobial agents
CA2188508A1 (en) Gonadotropins with non-native disulfide bridges
CA2234611A1 (en) New phenylamidine derivatives, processes for preparing them and their use as pharmaceutical compositions
CA2022081A1 (en) Treatment of hyperlipidemia with 15-keto-prostaglandin compounds

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)